Back to VRTX Overview
NMS · Valuation Lab
VRTX
Vertex Pharmaceuticals Incorporated
Last$484.83
Market cap122.8B
EV/EBITDA22.6x
Intrinsic value
$416.65
MoS -16.4% · Fairly Valued
Assuming 15.0% FCF margin and 12.5% Y1–5 growth.
Upside to price
EV (DCF)99.7B
Terminal share76%
Expected IV$411.89
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 76% of EV
PV of stage FCFs24.1B
PV of terminal value75.5B
Enterprise value99.7B
Net cash / (debt)5.9B
Equity value105.5B
Intrinsic value / share$416.65
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 14.2B | 2.1B | 2B | 94.3% |
| Y2 | 15.9B | 2.4B | 2.1B | 89.0% |
| Y3 | 17.9B | 2.7B | 2.3B | 84.0% |
| Y4 | 20.2B | 3B | 2.4B | 79.2% |
| Y5 | 22.7B | 3.4B | 2.5B | 74.7% |
| Y6 | 24.1B | 3.6B | 2.5B | 70.5% |
| Y7 | 25.6B | 3.8B | 2.6B | 66.5% |
| Y8 | 27.2B | 4.1B | 2.6B | 62.7% |
| Y9 | 29B | 4.3B | 2.6B | 59.2% |
| Y10 | 30.8B | 4.6B | 2.6B | 55.8% |
| Terminal | — | — | 75.5B | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.